List of Mycapssa drug patents

Mycapssa is owned by Amryt.

Mycapssa contains Octreotide Acetate.

Mycapssa has a total of 10 drug patents out of which 0 drug patents have expired.

Mycapssa was authorised for market use on 26 June, 2020.

Mycapssa is available in capsule, delayed release;oral dosage forms.

Mycapssa can be used as use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide, use of oral octreotide for long-term maintenance treatment in acromegaly patients while avoiding concomitant administration of levonorgestrel.

The generics of Mycapssa are possible to be released after 28 December, 2040.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265812 AMRYT Pharmaceutical compositions and related methods of delivery
Sep, 2029

(6 years from now)

US9566246 AMRYT Pharmaceutical compositions and related methods of delivery
Sep, 2029

(6 years from now)

US8329198 AMRYT Pharmaceutical compositions and related methods of delivery
Sep, 2029

(6 years from now)

US8535695 AMRYT Pharmaceutical compositions and related methods of delivery
Sep, 2029

(6 years from now)

US11510963 AMRYT Method of treating diseases
Feb, 2036

(13 years from now)

US10695397 AMRYT Method of treating diseases
Feb, 2036

(13 years from now)

US11052126 AMRYT Method of treating diseases
Feb, 2036

(13 years from now)

US10238709 AMRYT Method of treating diseases
Feb, 2036

(13 years from now)

US11338011 AMRYT Method of treating diseases
Feb, 2036

(13 years from now)

US11141457 AMRYT Oral octreotide therapy and contraceptive methods
Dec, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jun 26, 2023

Drugs and Companies using OCTREOTIDE ACETATE ingredient

Market Authorisation Date: 26 June, 2020

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide; Use of oral octreotide for long-term maintenance treatment in acromegaly patients while avoiding concomitant administration of levonorgestrel

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in